Translating Aging

Jacob Kimball is the Head of Research and co-founder of NewLimit, a company aiming to develop epigenetic reprogramming therapies to treat age-related diseases and extend human healthspan. In this episode, Chris and Jacob have an in-depth discussion about NewLimit’s mission and approach. They explore how NewLimit is leveraging epigenetics and machine learning to search for new ways to reverse cell...

In today’s episode, Chris is joined by Dr. Matthew "Oki" O'Connor, CEO for Scientific Affairs at Cyclarity Therapeutics, a company focused on eliminating arterial plaque, a prevalent issue in old age. Dr. O'Connor shares his insights on the causes and effects of atherosclerosis, the leading cause of death worldwide, and how aging contributes to plaque build-up. The podcast emphasizes the need for...

Dr. Marco Quarta, CEO and Co-founder of Rubedo Life Sciences, joins Chris on today’s episode to discuss his company’s strategy of targeting pathologic cells to develop therapeutics for chronic degenerative conditions. The conversation covers the evolving definition of senescence and the challenges of identifying and classifying pathologic cells, which vary across different tissues and indications....

In today’s episode, Chris sits down with Kevin Caldwell, CEO, Co-Founder, and President of Ossium Health, a company that aims to improve human health and longevity through bioengineering - specifically using stem cell science to create materials for cell therapies. Together, they discuss Ossium’s approach: processing and banking of bone marrow from organ donors, which can then be cryopreserved and...

This week, we welcomes Peter Fedichev, an entrepreneur and scientist with over 20 years of experience in academic research and biotech business who has co-founded three biotech companies. He’s currently the co-founder & CEO of GERO, a longevity startup on a mission to hack aging.  In this episode, Chris and Peter discuss GERO’s goal to accelerate our understanding of aging and create a th...

This week, Chris welcomes Morten Scheibye-Knudsen, Associate Professor at the University of Copenhagen, who’s on a mission to understand, modulate and treat aging and age-related diseases. His research group, The Scheibye-Knudsen Lab, is trying to understand the cellular and organismal consequences of DNA damage & repair with the aim of developing interventions for aging. Morten is also one of...

Optimizing Healthspan through Longevity Medicine (Dr. Andrea Maier – The Center for Healthy Longevity) Dr. Andrea Maier is an internal medicine specialist, geriatrician, and researcher whose work focuses on age-related disease, cellular senescence, and the translation of longevity science into clinical practice. Among her academic appointments are professorships at the Free University, Amsterdam a...

In today’s episode, Chris welcomes Sebastian Brunemeier, a biotech VC and company builder focused on longevity and regenerative medicine. Sebastien is the Co-Founder and General Partner of Healthspan Capital, a longevity VC firm that invests in biotechnology startups developing therapies to slow or reverse aging, and the CEO and Co-Founder of ImmuneAGE Pharma, a new company based on a drug discove...

Joining Chris on the podcast today is Nils Regge, Co-founder and Managing Director of Apollo Health Ventures.  As a social entrepreneur, company creator, and biotech expert, Nils built Apollo Health Ventures in 2016 to help health tech companies develop methods to prevent and reverse the aging process and extend the healthy human life span.   At Apollo, Nils makes use of his dealmak...

In this episode of the BioAge podcast, Ann Beliën joins Chris Patil today to share the story behind Rejuvenate Biomed, and her journey into the longevity sector.  She started her career at Johnson & Johnson after receiving her postdoctoral degree, and during her tenure, she worked in scientific, operational, and strategic roles.  Twenty years later, she became the founder and CEO of...

Today’s guest on the podcast is Marc Bernegger, a serial tech entrepreneur who has been following developments in the field of longevity since 2009. Recently he became a founding partner of the Swiss company, Maximon, whose core missions is building companies and providing support to longevity entrepreneurs. Marc has worked for over a decade between two continents at this point, and his interest i...

Joining Chris today is Dr. Vadim Gladyshev, Professor of Medicine at Harvard Medical School, Director of Redox Medicine at Brigham and Women's Hospital, and a member of the National Academy of Sciences. The Gladyshev lab studies redox biology and trace elements as they relate to cancer, reproduction, and aging. Today, Dr. Gladyshev shares with us how his research group investigates the aging proce...

Joining Chris today is Alex Zhavoronkov, CEO and Co-founder of Insilico Medicine, an artificial intelligence–driven pharma-technology company with a mission to accelerate drug discovery and development. Alex is a lifelong advocate for longevity biotech and the author of The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy. Today, Alex shares the accomplishments tha...

Back in the host's chair this week, Bob Hughes welcomes Dr. Bill Evans, one of the world's foremost experts on muscle aging, to the podcast. Bill is adjunct professor of Human Nutrition at University of California Berkeley and an adjunct professor of medicine in the Geriatrics Program at Duke. Previously, he was vice president and head of Muscle Metabolism Discovery Performance Unit at GlaxoSmithK...

This week’s episode of Translating Aging features Robin Mansukhani, CEO and Co-founder of Deciduous Therapeutics, a company that aims to positively impact human healthspan by developing medicines which activate the endogenous immune mechanism responsible for the elimination of senescent cells. Today, Robin shares his insights on how senescent cells develop and how Deciduous Therapeutics eliminates...

In today’s episode of Translating Aging, Chris welcomes Mark Hamalainen, the founder and director of LessDeath, to discuss how to encourage the influx of talents into the longevity field. LessDeath is an organization on a mission to support the growth and effectiveness of the longevity industry’s workforce. Today, Mark shares with us his experience in the longevity space, why he founded LessDeath,...

On today’s episode of Translating Aging, Chris welcomes Tyler Golato and Laurence Ion to talk about VitaDAO, a collective accelerating research in human longevity and decentralized drug development.  The pair start the conversation off by discussing their company’s roots -  a previous business venture that sought to change the incentive structures around drug development.  VitaDAO w...

On today’s episode of Translating Aging, Chris welcomes Nathan Cheng, the program director at On Deck Longevity Biotech (ODLB), to discuss how ODLB is cultivating new founders and connecting people in the longevity biotech space. Nathan writes about the longevity biotech industry in his Longevity Marketcap Newsletter, is the founder of Longevity List which aims to connect job seekers, companies an...

In today's episode, Chris is joined by two leaders of the Alliance for Longevity Initiatives, A4LI, the first and only 501(c)(4) nonprofit organization founded with the goal of creating social and political action around the issues of combating age-related chronic conditions and increasing our number of healthy, disease-free years.  Sonia Arrison is a best-selling author, analyst, entrepreneu...

Today’s guest is Dr. Morgan Levine, an assistant professor of Pathology and Epidemiology at Yale School of Medicine. She is also a Founding Principal Investigator at Altos, a new biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience. Dr. Levine shares her expertise on biological aging, aging clocks, cellular reprogramming, and a peek into the rese...

Today’s guest is Dr. Thomas Rando, Professor, Neurology; Molecular, Cell and Developmental Biology, and a pioneer in stem cell biology and the biology of aging. Dr. Rando is the Director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles, and the co-founder and Chair of the Board of Directors at Fountain Therapeutics. In...

Dr. Marco Demaria is an Associate Professor in Cellular Ageing at the Medical Faculty of the University of Groningen. In 2018, he co-founded a start-up company, Cleara Biotech, devoted to developing anti-senescence drugs. Today, Dr. Demaria shares his insights and research on how senescence promotes aging and factors that promote the creation of senescent cells. In this episode, Dr. Demaria explai...

The TAME trial and beyond (Dr. Nir Barzilai) Dr. Nir Barzilai is the founding director of the Institute for Aging Research, the Nathan Shock Center of Excellence in the Basic Biology of Aging, and the Paul F. Glenn Center for the Biology of Human Aging Research at Albert Einstein College of Medicine of Yeshiva University. He is also the author of the book Age Later . Today, Dr. Nir brings his expe...

Professor Steven Austad is a distinguished researcher in geroscience and the Protective Life Endowed Chair in Healthy Aging at the University of Alabama at Birmingham. He's also the Director of the Nathan Shock Center at UAB and the Senior Scientific Director of the American Federation for Aging Research. Today, Professor Austad joins Bob Hughes to discuss the biology of aging. He begins by narrat...

Dr. Nabiha Saklayen is CEO & co-founder of Cellino, a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies. Cellino’s proprietary technology aims to make personalized stem cell-derived therapies scalable for the first time. Dr. Saklayen received her Ph. D. in Physics from Harvard University as a Howard Hughes Medical Inst...